Development of a Molecular Panel to Detect Febrile Rash Illnesses

Phase I SBIR proposals will be accepted. Fast-track proposals will not be accepted. Phase I clinical trials will not be accepted. Number of anticipated awards: 1 Budget (total costs): Phase I up to $243,500 for up to 6 months; Phase II of up to $2,045,816 and a Phase II duration of up to 2 years PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Background Clinically, it is very difficult to determine the pathogen responsible for febrile exanthems, which is concerning for those pathogens that are highly infectious (e.g., measles) or pose a risk for congenital infections (e.g., rubella). The clinical presentation of these viruses is mimicked by less pathogenic viruses such as parvovirus B19 (parvo-B19) and human herpesvirus 6 (HHV-6) which can lead to misdiagnosis, especially for sporadic cases. Therefore, laboratory confirmation of suspected disease is imperative to ensure the patient receives appropriate care and that an appropriate public health response is initiated. Currently, no assay targets a complete comprehensive group of viruses associated with febrile exanthems.